Kyverna Therapeutics (KYTX) Liabilities and Shareholders Equity (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Liabilities and Shareholders Equity data on file, last reported at $257.0 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 1.39% year-over-year to $257.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $964.5 million (down 23.91% YoY) and the FY2025 annual result came in at $293.8 million, down 3.55% from the prior year.
• Liabilities and Shareholders Equity retreated to $257.0 million in Q1 2026, from $293.8 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $390.0 million in Q1 2024 to a low of $75.2 million in Q4 2023.
• A 4-year average of $269.7 million and a median of $277.2 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity surged 305.14% — and 2025, when it tumbled 44.82%.
• Tracing KYTX's Liabilities and Shareholders Equity over 4 years: stood at $75.2 million in 2023, then surged by 305.14% to $304.6 million in 2024, then dropped by 3.55% to $293.8 million in 2025, then retreated by 12.53% to $257.0 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $257.0 million (Q1 2026), $293.8 million (Q4 2025), and $187.2 million (Q3 2025), per Business Quant data.